Olema Pharmaceuticals, Inc. (OLMA)

10,15 +0,15 (+1,50%) Alla chiusura: 04:00PM EDT

Olema Pharmaceuticals, Inc.

780 Brannan Street
San Francisco, CA 94103
United States
415-651-3316
https://olema.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 74

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Sean P. Bohen M.D., Ph.D.	President, CEO & Director	1M	N/D	1967
Mr. Shane William Charles Kovacs M.B.A.	Chief Operating & Financial Officer	726,17k	N/D	1974
Dr. Naseem Zojwalla M.D.	Chief Medical Officer	775,48k	N/D	1973
Mr. Geoffrey Mogilner	Vice President of Investor Relations & Communications	N/D	N/D	N/D
Ms. Julie Dexter	Senior VP & Head of People	N/D	N/D	N/D
Dr. David C. Myles Ph.D.	Chief Discovery & Non-Clinical Development Officer	200k	N/D	1963
Ms. Demiana Faltaos Ph.D., Pharm.D.	VP & Head of Clinical Pharmacology	N/D	N/D	N/D
Mr. John B. Moriarty Jr., J.D.	Corporate Secretary	434,32k	N/D	1968
Ms. Sasha Austin CPA	VP of Finance & Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Olema Pharmaceuticals, Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.